Breaking News Instant updates and real-time market news.

RDY

Dr. Reddy's

$34.02

-0.09 (-0.26%)

, MNTA

Momenta

$16.30

0.05 (0.31%)

04:55
02/13/18
02/13
04:55
02/13/18
04:55

Wells Fargo to hold a summit

2018 Wells Fargo Generic Drug Summit will be held in Orlando on February 12-13.

RDY

Dr. Reddy's

$34.02

-0.09 (-0.26%)

MNTA

Momenta

$16.30

0.05 (0.31%)

CHRS

Coherus Biosciences

$9.75

0.3 (3.17%)

AMPH

Amphastar

$18.50

0.1 (0.54%)

  • 21

    Feb

RDY Dr. Reddy's
$34.02

-0.09 (-0.26%)

10/27/17
10/27/17
UPGRADE
Target $97

Equal Weight
Celgene upgraded to Equal Weight after expectations reset at Morgan Stanley
As previously reported, Morgan Stanley analyst Matthew Harrison upgraded Celgene to Equal Weight from Underweight, saying he believes expectations have been reset and the current price better reflects the clinical, commercial and generic risks the company faces. From here, he still sees the near-term risk related to Dr. Reddy's (RDY) and generics outweighing potential positive catalysts at the ECTRIMS and ASH meetings, Harrison tells investors, adding that the current level of the shares captures "some" of those risks. He lowered his price target on Celgene shares to $97 from $115.
09/21/17
MSCO
09/21/17
UPGRADE
MSCO
Overweight
Dr. Reddy's upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Sameer Baisiwala upgraded last night Dr. Reddy's Laboratories to Overweight with a price target of 3,133 rupees.
08/31/17
LYON
08/31/17
UPGRADE
LYON
Outperform
Dr. Reddy's upgraded to Outperform from Underperform at CLSA
07/28/17
LYON
07/28/17
DOWNGRADE
LYON
Sell
Dr. Reddy's downgraded to Sell from Buy at CLSA
MNTA Momenta
$16.30

0.05 (0.31%)

10/05/17
GSCO
10/05/17
NO CHANGE
Target $14
GSCO
Neutral
Momenta price target cut to $14 following Mylan gCopaxone approval at Goldman
Goldman analyst Dana Flanders lowered Momenta (MNTA) estimates and cut its price target on share to $14 from $18 following Mylan's (MYL) generic Copaxone approval. The analyst maintained a Neutral rating on Momenta given uncertainties on how the gCopaxone market will play out and lack of near-term pipeline catalysts.
10/04/17
10/04/17
DOWNGRADE
Target $15

Hold
Momenta downgraded after Mylan generic Copaxone approval at Stifel
As previously reported, Stifel analyst Thomas Shrader downgraded Momenta (MNTA) to Hold from Buy, saying that Mylan (MYL) receiving FDA approval of its 40 mg/mL and 20 mg/mL generic Copaxone variants is a "clear negative" for Momenta's Glatopa franchise. Based on that news, he has cut his forecast for Glatopa revenue and lowered his price target on Momenta shares to $15 from $22.
10/04/17
STFL
10/04/17
DOWNGRADE
STFL
Hold
Momenta downgraded to Hold from Buy at Stifel
10/04/17
JPMS
10/04/17
NO CHANGE
JPMS
Overweight
JPMorgan says generic Copaxone approval 'meaninful positive' for Mylan
Mylan's (MYL) generic Copaxone approval, 9-12 months ahead of investor expectations, represents a "meaningful positive" for the story and will "substantially derisk/support" upside to 2017 and 2018 estimates, JPMorgan analyst Chris Schott tells investors in a research note. The analyst reiterates an Overweight rating on the shares. For Teva (TEVA), the approval puts further pressure on the company's "already challenged" near-term earnings profile and delevering efforts, Schott writes. The analyst keeps a Neutral rating on the shares. The analyst believes the earlier than expected approval for Mylan represents a setback for Momenta Pharmaceuticals' (MNTA) generic Copaxone opportunity. Schott had assumed the company's Glatopa would be the first generic version of Copaxone 40mg to enter the market, but he notes the product has been delayed due to manufacturing issues at a Pfizer (PFE) plant handling fill/ for the drug. The analyst, however, continues to see a "large and fairly durable" generic opportunity for Glatopa. He keeps an Overweight rating on Momenta shares, which are down 27% in premarket trading to $12.75. Mylan is up 17% to $38.20 while Teva is down 15% to $15.95.
CHRS Coherus Biosciences
$9.75

0.3 (3.17%)

09/27/17
FBCO
09/27/17
NO CHANGE
Target $17
FBCO
Outperform
Coherus Biosciences price target lowered to $17 from $24 at Credit Suisse
Credit Suisse analyst Alethia Young lowered her price target for Coherus Biosciences (CHRS) to $17 from $24 as she is pushing her worldwide launch timeline assumption to 2022 from 2020 for the biosimilar Humira from AbbVie (ABBV). The analyst reiterates an Outperform rating on Coherus Biosciences shares.
09/15/17
JEFF
09/15/17
NO CHANGE
Target $107
JEFF
Buy
AbbVie price target raised to $107 from $94 at Jefferies
Jefferies analyst Jeffrey Holford raised his price target for AbbVie (ABBV) to $107 after Coherus Biosciences (COHR) failed to gain institution of an inter partes review on a key formulation Humira patent. The analyst says his two-stage thesis on AbbVie has been that consensus expectations for U.S. Humira biosimilars would be pushed back, allowing investors to "finally focus" on the value inside the rest of the company and the pipeline. In a research note titled "Stage I Complete; More Upside on Offer from Stage II," Holdford reiterates AbbVie as his Top Pick with a Buy rating.
09/15/17
PIPR
09/15/17
NO CHANGE
Target $100
PIPR
Overweight
AbbVie price target raised to $100 from $85 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss raised his price target for AbbVie (ABBV) to $100 after pushing out a U.S. biosimilar entry for Humira by two years. The recent denials by the Patent Trial and Appeal Board of all four of Coherus Bioscience's (CHRS) inter partes review petitions reinforce the patentability of Humira's formulation, Purkiss tells investors in a research note. The analyst pushed out his view of the likely timing of the first U.S. biosimilar launch versus Humira to the second half of 2022 from the second half of 2020. He estimates Humira will still account for 58% of AbbVie's total revenue in 2020. The analyst reiterates an Overweight rating on the shares.
11/07/17
SBSH
11/07/17
NO CHANGE
Target $23
SBSH
Buy
Citi sees value in Coherus even without Humira
Citi analyst Mohit Bansal lowered his price target for Coherus Biosciences shares to $23 from $33 after removing Humira and Enbrel from his model. Investors will unlikely assign value to Humira and Enbrel biosimilars "anytime soon" given the lack of intellectual property clarity and competition, Bansal tells investors in a research note. The analyst, however, still sees value in Coherus even without Humira. The company's meeting with the FDA is key and a subsequent resubmission will likely make investors more confident in Neulasta biosimilar approval, Bansal contends. He keeps a Buy rating on Coherus Biosciences.
AMPH Amphastar
$18.50

0.1 (0.54%)

11/09/17
RAJA
11/09/17
DOWNGRADE
RAJA
Market Perform
Amphastar downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Elliot WIlbur downgraded Amphastar to Market Perform after shares have hit his price target and said he sees few catalysts ahead to drive estimates upward.
03/14/17
03/14/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Corning (GLW) downgraded to Neutral from Buy at Goldman with analyst Doug Clark citing valuation with the stock up 33% since his upgrade back in April of 2016. The analyst keeps a $29 price target for the shares. 2. Amphastar (AMPH) downgraded to Outperform from Strong Buy at Raymond James with analyst Elliot Wilbur saying he sees an increased near-term risk profile following indications from FDA that Amphastar may have to withdraw its epinephrine product. 3. Abbott (ABT) downgraded to Market Perform from Outperform at BMO Capital. 4. GGP (GGP) downgraded to Neutral from Buy at UBS with analyst Jeremy Metz saying he does not see headwinds in the sector easing in the short term and cut his price target for GGP shares to $25 from $28. 5. Harmonic (HLIT) downgraded to Hold from Buy at Drexel Hamilton. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/21/17
WELS
07/21/17
NO CHANGE
WELS
Outperform
Amphastar 'David-vs-Goliath' win over Momenta a major victory, says Wells Fargo
Wells Fargo analyst David Maris said a jury's ruling that a Momenta (MNTA) patent was invalid and unenforceable is a very positive outcome for Amphastar (AMPH) in its "David-vs-Goliath-type" case. While he expects Momenta and partner Novartis' (NVS) Sandoz to appeal, Maris thinks this ruling puts Amphastar in a good position for any future potential settlement talks. Maris does not think investors should "count on any windfall" for Amphastar, but he does think, if approved, this could be an over $50M opportunity and keeps an Outperform rating on the stock, which is up 2% to $18.32 in afternoon trading.
01/26/18
WELS
01/26/18
NO CHANGE
WELS
Outperform
Wells Fargo more excited about Amphastar pipeline on further examination
Wells Fargo analyst David Maris said his review of new Drug Master Files added to the FDA database in Q4 leads him to believe Amphastar filed a DMF for the active ingredient to a number of leading respiratory drugs, ipratropium, in November 2017. Amphastar confirmed the filing and that it is related to their pipeline, but would not comment what specific branded product this filing targets, said Maris, who believes the company is working on generic versions of Advair, Flovent, and now possibly Atrovent/Combivent. Maris maintains his Outperform rating on Amphastar shares.

TODAY'S FREE FLY STORIES

PEG

PSEG

$49.18

0.65 (1.34%)

, COG

Cabot Oil & Gas

$23.88

0.63 (2.71%)

20:25
02/22/18
02/22
20:25
02/22/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PEG

PSEG

$49.18

0.65 (1.34%)

COG

Cabot Oil & Gas

$23.88

0.63 (2.71%)

HUN

Huntsman

$33.32

-0.27 (-0.80%)

CNK

Cinemark

$39.72

0.1 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 26

    Feb

  • 28

    Feb

  • 05

    Mar

  • 23

    May

DOVA

Dova Pharmaceuticals

$32.78

-0.08 (-0.24%)

19:57
02/22/18
02/22
19:57
02/22/18
19:57
Syndicate
Dova Pharmaceuticals 2.5M share Secondary priced at $32.00 »

JPMorgan, Jefferies and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 23

    Feb

SPY

SPDR S&P 500 ETF Trust

$270.40

0.35 (0.13%)

, SPX

S&P 500

19:25
02/22/18
02/22
19:25
02/22/18
19:25
Periodicals
Breaking Periodicals news story on SPDR S&P 500 ETF Trust, S&P 500 »

Treasury Sec.: Trump…

SPY

SPDR S&P 500 ETF Trust

$270.40

0.35 (0.13%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMAB

OMA Airports

$41.47

0.33 (0.80%)

19:10
02/22/18
02/22
19:10
02/22/18
19:10
Hot Stocks
OMA Airports reports Q4 passenger traffic up 1.8% »

Total terminal passenger…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIV

Aimco

$38.28

0.28 (0.74%)

19:05
02/22/18
02/22
19:05
02/22/18
19:05
Hot Stocks
Aimco acquires Bent Tree apartment community for $160M »

Apartment Investment and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KDMN

Kadmon

$3.60

-0.16 (-4.26%)

18:49
02/22/18
02/22
18:49
02/22/18
18:49
Hot Stocks
Kadmon updates 'positive' results from Phase 2 study of KD025 in cGVHD »

Kadmon announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASR

Asur

$182.83

1.49 (0.82%)

18:47
02/22/18
02/22
18:47
02/22/18
18:47
Hot Stocks
Asur reports Q4 passenger traffic down 4% »

ASUR's total…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USB

U.S. Bancorp

$54.27

-0.83 (-1.51%)

18:45
02/22/18
02/22
18:45
02/22/18
18:45
Periodicals
Judge criticizes U.S. Bancorp deal to sidestep prosecution, Bloomberg reports »

U.S. District Judge Lewis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 30

    May

KZIA

Kazia Therapeutics

$4.99

0.43 (9.43%)

18:36
02/22/18
02/22
18:36
02/22/18
18:36
Hot Stocks
Kazia granted orphan status for glioblastoma treatment »

The FDA granted Kazia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OBE

Obsidian Energy

$0.98

0.0183 (1.91%)

18:29
02/22/18
02/22
18:29
02/22/18
18:29
Hot Stocks
Obsidian Energy reports 126% reserve replacement of 2017 production »

Obsidian Energy said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OBE

Obsidian Energy

$0.98

0.0183 (1.91%)

18:27
02/22/18
02/22
18:27
02/22/18
18:27
Hot Stocks
Obsidian Energy names Jay Thornton chairman of the board »

Obsidian Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSRM

SSR Mining

$8.33

0.06 (0.73%)

18:27
02/22/18
02/22
18:27
02/22/18
18:27
Earnings
SSR Mining reports Q4 adjusted EPS 2c, consensus 7c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

SSRM

SSR Mining

$8.33

0.06 (0.73%)

18:21
02/22/18
02/22
18:21
02/22/18
18:21
Hot Stocks
SSR Mining sees 2018 gold production 340K gold equivalent ounces »

SSR Mining expect to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

IVC

Invacare

$17.97

-0.28 (-1.53%)

18:20
02/22/18
02/22
18:20
02/22/18
18:20
Hot Stocks
Invacare names Kathleen Leneghan as CFO, effective immediately »

Invacare announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

SHCAY

Sharp

$8.21

-0.025 (-0.30%)

18:18
02/22/18
02/22
18:18
02/22/18
18:18
Periodicals
Sharp drops legal action against Hisense over TV brands, Nikkei reports »

Sharp has dropped legal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$40.91

0.35 (0.86%)

18:17
02/22/18
02/22
18:17
02/22/18
18:17
Periodicals
GM seeks South Korean aid to bolster local unit, Nikkei Asian Review reports »

General Motors is seeking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJI

South Jersey Industries

$26.34

0.23 (0.88%)

18:14
02/22/18
02/22
18:14
02/22/18
18:14
Earnings
Breaking Earnings news story on South Jersey Industries »

South Jersey Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

TRTN

Triton International

$28.16

-0.4 (-1.40%)

18:13
02/22/18
02/22
18:13
02/22/18
18:13
Earnings
Triton International reports Q4 adjusted EPS 85c, consensus 80c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

SJI

South Jersey Industries

$26.34

0.23 (0.88%)

18:13
02/22/18
02/22
18:13
02/22/18
18:13
Earnings
Breaking Earnings news story on South Jersey Industries »

South Jersey Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

PAA

Plains All American

$20.97

-0.43 (-2.01%)

18:09
02/22/18
02/22
18:09
02/22/18
18:09
Hot Stocks
Plains All American's Cactus II pipeline fully committed »

Plains All American…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 07

    Mar

STX

Seagate

$51.36

-0.08 (-0.16%)

18:03
02/22/18
02/22
18:03
02/22/18
18:03
Initiation
Seagate initiated at Stifel »

Seagate resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

WDC

Western Digital

$85.53

-0.14 (-0.16%)

18:01
02/22/18
02/22
18:01
02/22/18
18:01
Initiation
Western Digital initiated at Stifel »

Western Digital resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$21.39

0.22 (1.04%)

17:56
02/22/18
02/22
17:56
02/22/18
17:56
Hot Stocks
Breaking Hot Stocks news story on HP Inc. »

HP Inc. sees higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 24

    Apr

  • 30

    May

BKD

Brookdale Senior Living

$7.18

-1.72 (-19.33%)

17:52
02/22/18
02/22
17:52
02/22/18
17:52
Downgrade
Brookdale Senior Living rating change at Stifel »

Brookdale Senior Living…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

AQMS

Aqua Metals

$2.62

-0.25 (-8.71%)

17:52
02/22/18
02/22
17:52
02/22/18
17:52
Hot Stocks
Philotimo Fund reports 6.5% stake in Aqua Metals »

Philotimo Fund purchased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.